Pioglar( pioglitazone)

Pioglar( pioglitazone) analogues:

Pioglar( pioglitazone) statement:

Manufacturer:

"Ranbaxy Laboratories Limited", India

Pioglara Active ingredients:

Pioglitazone.

release form Pioglara:

  • Tablets 15 mg № 30, № 100.
  • Tablets 30 mg № 30, № 100.

Who can Pioglar?

Non-insulin-dependent diabetes mellitus( type II).Pioglar can be used in the form of monotherapy or in combination with sulfonylureas, metformin or insulin.

How to use Pioglar?

Pioglar is taken adults orally once a day regardless of food intake. The dose of the drug is selected individually. The initial dose of pioglitazone is 15 mg, if necessary, the dose can be increased - 15 to 30 mg once a day. The maximum daily dose is 45 mg, with combined therapy 30 mg / day. With combined therapy with insulin, the initial dose of pioglitazone is 15 - 30 mg per day, the dose of insulin remains the same, or decreases by 10 - 25%.

Pioglitazone should be given with caution to patients with edema. Do n

ot prescribe pioglitazone to patients in the presence of clinical manifestations of liver disease in the active phase and with an increase in ALT levels more than 2.5 times higher than the upper limit of the norm. With a moderate increase in the activity of liver enzymes, caution should be initiated or continued treatment of pioglitazone. During treatment with pioglitazone, patients with liver pathology should regularly monitor levels of hepatic enzymes. The development of hypoglycemia in combination therapy necessitates a reduction in the dose of concomitant sulfonamides or insulin. In patients with insulin resistance and apodulyatornym cycle in predmenopazualny during treatment may induce ovulation, which can lead to unwanted pregnancy, so need contraception.

Against the background of renal failure, dose adjustment is not required. The development of anemia, a decrease in hemoglobin and a decrease in hematocrit may be associated with an increase in the volume of plasma and do not show any clinically significant hematologic effects.

The use of pioglitazone in children is not recommended.

Influence on ability to drive vehicles and work with dangerous mechanisms.

When using the drug should refrain from driving and working with potentially dangerous mechanisms.

Side effects of Pioglar.

The drug is well tolerated. Possible hypoglycemia, anemia, decreased hemoglobin and gemotakrita, reduction of bilirubin, elevated ALT( alanine aminotransferase), CK( kreatininfosfotazy), headache, sinusitis, myalgia, disruption of tooth enamel, pharyngitis. Who is contraindicated in Pioglar?

Pioglitazone is contraindicated in patients with known hypersensitivity to any component of the drug, with diabetic ketoacidosis. Pioglitazone is contraindicated during pregnancy and in women during lactation.

Interaction Pioglar.

Derivatives of sulfonamides, metformin and insulin potentiate hypoglycemia. With the simultaneous use of pioglitazone and oral contraceptives, a reduction in the effectiveness of contraception is possible. Ketoconazole inhibits the metabolism of pioglitazone.

Overdose of Pioglar.

Symptoms: increased side effects( hypoglycemia).

Treatment: symptomatic therapy.